Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Araceli Biosciences has raised a total of $11.2 million, including $7.2 million in Seed funding, to improve its AI-driven imaging technology for drug discovery. Keymed Biosciences Inc. has received IND approval for its CDH17-targeted ADC, CM518D1, which is currently undergoing Phase I/II trials for solid tumors in China.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
